Re-VOLVE: Phase II clinical trial in women with ovarian cancer progressing post-PARP inhibitor with treatment adapted to real-time assessment of evolving genomic resistance. Circulating tumor DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results